Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

David Socks Biography and Net Worth

CFO & Chief Bus. Officer of HilleVax

David Socks is Chief Financial Officer and Chief Business Officer of HilleVax. David was formerly a Venture Partner with Frazier Healthcare Partners, where he co-founded Arcutis (NASDAQ: ARQT), Passage Bio (NASDAQ: PASG) and Phathom Pharmaceuticals (NASDAQ: PHAT). At Phathom, he served as the founding CEO through the company’s IPO, then as CFO, and currently as strategic advisor and director. At Frazier, David also co-founded and served as CEO and/or executive chairman of multiple private companies. Prior to joining Frazier, he co-founded Incline Therapeutics where he served as the company’s President and COO until its sale to The Medicines Company. Previously, David was a Venture Partner at Windamere Venture Partners, where he co-founded multiple private and public companies including Cadence Pharmaceuticals (NASDAQ: CADX; acquired by Mallinckrodt) where he served as Senior Vice President of Corporate Development and Strategy. He has also worked in private equity and management consulting.

David holds a B.S. from Georgetown University and an M.B.A. from Stanford University.

How do I contact David A. Socks?: The corporate mailing address for Mr. Socks and other HilleVax executives is , , . HilleVax can also be reached via phone at 617-213-5054 and via email at [email protected]. Learn More on David A. Socks' contact information.
Has David A. Socks been buying or selling shares of HilleVax?: David A. Socks has not been actively trading shares of HilleVax within the last three months. Learn More on David A. Socks' trading history.
Who are HilleVax's active insiders?: HilleVax's insider roster includes Robert Hershberg (CEO, President & Chair), Aditya Kohli (COO & Director ), and David Socks (CFO & Chief Bus. Officer ). Learn More on HilleVax's active insiders.
Are insiders buying or selling shares of HilleVax?: During the last twelve months, HilleVax insiders bought shares 2 times. They purchased a total of 10,100 shares worth more than $149,550.00. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 123,039 shares worth more than $987,111,242.27. The most recent insider tranaction occured on April, 5th when Director Aditya Kohli sold 6,000 shares worth more than $86,640.00. Insiders at HilleVax own 29.3% of the company. Learn More about insider trades at HilleVax.
Information on this page was last updated on 4/5/2024.

David A. Socks Insider Trading History at HilleVax

David A. Socks Buying and Selling Activity at HilleVax

HilleVax Company Overview

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $12.02

$11.79

$12.40

50 Day Range

MA: $15.84

$11.86

$19.75

2 Week Range

Now: $12.02

$9.94

$20.22

Volume

52,387 shs

Average Volume

135,312 shs

Market Capitalization

$597.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Your Money is Not Safe

From American Alternative | Ad

CLICK HERE TO GET YOUR GUIDE NOW